Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

FOURIER

FDA approves evolocumab to prevent heart attack, stroke, and coronary revascularization

FDA approves evolocumab to prevent heart attack, stroke, and coronary revascularization

The U.S. Food and Drug Administration (FDA) has approved evolocumab as the first PCSK9 inhibitor to prevent heart attacks, strokes and coronary revascularizations in adults with established cardiovascular disease. The approval was supported by data from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition…

read more »
PlayESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

ESC/EAS Task Force issues updated clinical guidance for PCSK9 inhibitors

This Task Force from the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) has considered new evidence from cardiovascular outcomes studies with evolocumab (FOURIER) and bococizumab (now terminated), new analyses and genetic studies.t Taking account of the cost of these agents, the Task…

read more »
New network meta-analysis of PCSK9 inhibitor efficacy

New network meta-analysis of PCSK9 inhibitor efficacy

This analysis reaffirms the efficacy of PCSK9 monoclonal antibody therapy added to medium- to high-intensity statin therapy in lowering LDL cholesterol. The authors reviewed 69 trials of lipid-lowering therapies that enrolled patients requiring further LDL cholesterol reduction while on maximally tolerated medium- or high-intensity statin…

read more »
More from FOURIER: Evolocumab effective in diabetics, no impact on glucose control

More from FOURIER: Evolocumab effective in diabetics, no impact on glucose control

The latest report from the FOURIER (Further cardiovascular Outcomes Research with PCSK9 Inhibition in subjects with Elevated Risk) trial (1) shows that treatment with the PCSK9 inhibitor evolocumab was similarly effective in patients with and without diabetes. Importantly, evolocumab did not increase the risk of…

read more »
FOURIER update: new impetus for guideline groups to reconsider LDL targets

FOURIER update: new impetus for guideline groups to reconsider LDL targets

  ESC Congress 2017: Not lower is better but lowest is best, according to findings from a new analysis from the FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial with the PCSK9 inhibitor evolocumab (1). According to lead author…

read more »
NLA 2017 recommendations: Who should benefit from PCSK9 inhibition?

NLA 2017 recommendations: Who should benefit from PCSK9 inhibition?

Dr Peter Lansberg, PCSK9 Forum News Editor discusses these latest recommendations from the US National Lipid Association. The National Lipid Association has recently published updated guidance for the use of PCSK9 inhibitors (1). This statement has courted controversy with recommendations for using these efficacious agents…

read more »
PlayThe Word from ACC 2017 – Implications for Practice

The Word from ACC 2017 – Implications for Practice

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board discuss implications from FOURIER for clinical practice.

read more »
PlayThe Word from ACC 2017  – Key Results

The Word from ACC 2017 – Key Results

The highlight of ACC 2017 was the FOURIER trial, representing the culmination of the PCSK9 revolution. Here PCSK9 Forum Co-Editor Professor John Chapman and experts from the PCSK9 Forum Editorial Board dissect the key results and messages from FOURIER.

read more »
PlayAccess to PCSK9 inhibitor treatment: NLA survey provides important pointers

Access to PCSK9 inhibitor treatment: NLA survey provides important pointers

Professor Dean G. Karalis (Director of Preventive Cardiology, Pennsylvania Hospital, USA) discusses the issues and how to counter these. FOURIER and SPIRE-2 have clearly shown the benefits of lowering LDL cholesterol beyond current targets in very high risk patients. However, from a routine practice view,…

read more »
PlayFOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER in the Hot Seat: What are the Implications for practice and access?

FOURIER was a landmark trial for PCSK9 inhibition, showing significant reduction in cardiovascular events with evolocumab in very high risk patients on maximally tolerated lipid lowering therapy. The results from FOURIER, together with those from SPIRE-2 in patients at higher baseline LDL cholesterol levels, clearly…

read more »
PlayDr Brian Ference sets the record straight on questions about benefit in FOURIER

Dr Brian Ference sets the record straight on questions about benefit in FOURIER

In discussions at ACC.2017, some have suggested that the results of FOURIER were less than anticipated from the meta-analysis of statin trials by the Cholesterol Treatment Trialists’ Collaboration (CTTC) (1). PCSK9 Forum Editor Dr Brian Ference (Division of Cardiovascular Medicine, Wayne State University School of…

read more »
PlayEvents are the driver in PCSK9 cardiovascular outcomes trials

Events are the driver in PCSK9 cardiovascular outcomes trials

A recurrent question at ACC.2017 was why FOURIER had a short duration of follow-up, given the average duration of the statin trials was typically in the region of 4-5 years. This debate has been fanned by colourful but misinformed reports in the investment media (1).’…

read more »